Skip to main content
Clinical Trials/CTRI/2025/12/099861
CTRI/2025/12/099861Not yet recruitingNot Applicable

ASSOCIATION OF GHRELIN GENE (GHRL) POLYMORPHISM (rs4684677) WITH COGNITIVE STATUS IN T2DM

Maulana Azad Medical College1 site in 1 country90 target enrollmentStarted: January 20, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
90
Locations
1

Study Overview

Brief Summary

The primary aim is to detect GHRL rs4684677 polymorphism and measure plasma ghrelin levels alongside cognitive function in T2DM patients versus controls. T2DM drives cognitive decline via insulin resistance and inflammation, with ghrelin offering neuroprotective potential. This study links genetic variation, hormone levels, and MoCA-assessed cognition to elucidate early DCI mechanisms

Study Design

Study Type
Observational

Eligibility Criteria

Ages
35.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • For Cases:Known diabetic patients diagnosed with T2DM,atleast for the last 5 years as per ADA criteria.On treatment,without any other known metabolic,surgical,or psychiatric comorbid condition.
  • For Control:Healthy volunteers.

Exclusion Criteria

  • For Cases: Patient admitted with acute complications of Diabetes mellitus.
  • For Control: history of any substance abuse which may affect cognitive function.

Investigators

Sponsor Class
Government medical college
Responsible Party
Principal Investigator
Principal Investigator

Dr Smita Kaushik

Maulana Azad Medical College

Study Sites (1)

Loading locations...

Similar Trials